Phoenix Tissue Repair, Inc.   Report issue

For profit Phase 2
Founded: Boston MA United States (2015)

Organization Overview

First Clinical Trial
2019
NCT03752905
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Phoenix Tissue Repair | Phoenix Tissue Repair, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

human collagen 7 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Epidermolysis Bullosa (Phase 2)

Epidermolysis Bullosa Dystrophica (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 1